Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran TQT study in healthy adults
NCT06589726Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (4 arms), sponsored by Merck KGaA. Primary endpoint: Placebo-Corrected Change from Baseline in Heart Rate-Corrected QT Interval by Fridericia's Formula. Started Sep 2024; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT06589726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589726.